Document 22 - Assort Design

Document #22 Medical Affairs

Source: url • Audience: medical_affairs • Status: completed

Routing confidence: 85% • Candidates: Medical Affairs, R&D, Commercial

Routing reasons: The document focuses on a specific medical condition (MASH) and its treatment, indicating content aimed at healthcare professionals.; References to FDA-approved treatments, disease pathology, and scientific citations suggest it is intended for a medically informed audience.; The presence of patient advocacy information and therapeutic focus aligns with the medical affairs domain.

Back to Request Back Home

Home - Madrigal Medical Professionals Contact Us Search for: Back Region United States Germany About Our Leaders Community Corporate Giving Therapeutic Focus What is MASH? Our Medicine Careers & Culture Investors & Media Leading the Fight Against MASH Our innovative research led to the first breakthrough in MASH treatment. And we’re just getting started. More About Madrigal COMPANY NEWS European Commission Grants Approval of Our Medicine. Read more Pam, patient advocate Delivering a Breakthrough Treatment Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for meta...

Show full document

Home - Madrigal Medical Professionals Contact Us Search for: Back Region United States Germany About Our Leaders Community Corporate Giving Therapeutic Focus What is MASH? Our Medicine Careers & Culture Investors & Media Leading the Fight Against MASH Our innovative research led to the first breakthrough in MASH treatment. And we’re just getting started. More About Madrigal COMPANY NEWS European Commission Grants Approval of Our Medicine. Read more Pam, patient advocate Delivering a Breakthrough Treatment Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse liver scarring (fibrosis) and resolve MASH before patients experience the devastating complications of cirrhosis. Madrigal’s ambitious research program led to the first U.S. Food and Drug Administration (FDA)-approved treatment in MASH. Our Medicine Shining a Light on MASH Shining a Light on MASH Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious form of fatty liver disease that occurs when fat in the liver becomes toxic, damaging liver cells. The chronic and progressive nature of the disease can cause significant damage over time, including inflammation and scarring, or fibrosis. Fibrosis can progress quickly and be unpredictable, often resulting in cirrhosis and decompensated liver disease. MASH is the leading cause of liver transplantation in the U.S. for women and is expected to soon become the leading cause for men. More About MASH Careers & Culture Interested in transforming care of people living with MASH? Learn more about Madrigal’s purpose, Core Values and culture. Explore Life at Madrigal News Read More News Read More News Events View More Events View More Events References Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8(10):661-8. Heyens LJM, Busschots D, Koek GH, et al. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med (Lausanne) . 2021;8:615978. Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol . 2018;113(11):1649-1659. Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open . 2020;3(2):e1920294. About Therapeutic Focus Our Medicine Careers & Culture Investors & Media Contact Us Terms of Use Transparency Privacy Cookies U.S. Consumer Health Privacy Manage Cookie Preferences Your Privacy Choices © 2026 Madrigal Pharmaceuticals, Inc. All rights reserved. The information on this website is intended for residents of the United States only. Madrigal Patient Support is a registered trademark of Madrigal Pharmaceuticals, Inc. US-CORP-MDGL-00002 You are now leaving madrigalpharma.com. By clicking this link you will be redirected to a website that is neither owned nor controlled by Madrigal. Madrigal is not responsible for the content or services of this site. Continue Stay Here

One-line Summary

Madrigal Pharmaceuticals pioneered the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), addressing a critical unmet need in halting liver fibrosis and preventing serious liver-related complications.

Decision Bullets

Expected: 3–5 bullets.

Scientific Summary: MASH involves toxic fat-induced liver cell damage progressing to fibrosis and cirrhosis, necessitating novel therapeutics to prevent end-stage liver disease.
Evidence Gaps: Long-term efficacy and safety data of the new treatment in diverse populations remain limited.
Medical Insights: Early intervention targeting fibrosis could reduce liver transplant rates and mortality associated with MASH.
Stakeholder Considerations: Patient advocacy is critical given disease burden, and payers must evaluate cost-effectiveness of novel therapies.
Next Steps: Further research needed on biomarkers for non-invasive diagnosis and therapy monitoring, plus expanded clinical trials.

Mind Map

mindmap
  root((Madrigal & MASH))
    Research
      - First FDA-approved treatment
      - Novel therapeutics development
    Disease
      - Metabolic dysfunction-associated steatohepatitis (MASH)
      - Progresses to fibrosis, cirrhosis, liver failure
      - Leading cause of liver transplant
    Clinical Impact
      - Halting/reversing liver scarring
      - Preventing advanced liver disease
    Evidence Gaps
      - Long-term safety/efficacy
      - Biomarker validation
    Stakeholders
      - Patients & advocates
      - Healthcare providers
      - Payers
    Next Steps
      - Expanded clinical trials
      - Non-invasive diagnostics
      - Monitoring treatment outcomes

If needed, use the in-page "View source" button on the job detail page to see the raw mind map.

Key Clues

MASH is a serious progressive liver disease
First FDA-approved treatment developed by Madrigal
MASH leads to fibrosis, cirrhosis, liver failure
MASH is major cause of liver transplantation
Focus on halting/reversing liver scarring
Formerly known as NASH
High unmet medical need

Tag Intelligence

No inferred domain yet.

No canonical tags yet.

View Tag Insights

Tool Summary

Low support: fewer than 3 cited claims.

Citations: 0

No citations available yet.

No risk flags detected.